Stemline Therapeutics, Inc IPO

In January 2013, an Edwards Wildman team advised Stemline Therapeutics, Inc. on its Initial Public Offering. Trumpeted by the BioWorld headline "Stemline Therapeutics Is First Biotech IPO of 2013", the offering was well received by investors, soaring 15% on its first day of trading on the NASDAQ. The deal involved Edwards Wildman corporate, finance, insurance and intellectual property team members from Boston and Chicago.
Posted on January 1, 2013